_new-treatment-options-for-cll-patients.jpg "New Treatment Options for CLL Patients from ibrutinib medication Video Screenshot Preview")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
⏲ Duration: 7 min 23 sec
✓ Published: 17-Dec-2015
✓ Published: 17-Dec-2015
Description:
In an exclusive interview, Dr. Tom Kipps, a CLL expert physician from the University of California in San Diego talks about new treatment options for CLL. Results from the Resonate Phase III study of Ibrutinib versus Ofatumumab in patients with relapsed or refractory Chronic Lymphocytic Leukemia was presented at the conference and the results were very positive for patients treated with Ibrutinib. Dr. Kipps goes on to explain that the study was a cross-over study so that patients could choose to
In an exclusive interview, Dr. Tom Kipps, a CLL expert physician from the University of California in San Diego talks about new treatment options for CLL. Results from the Resonate Phase III study of Ibrutinib versus Ofatumumab in patients with relapsed or refractory Chronic Lymphocytic Leukemia was presented at the conference and the results were very positive for patients treated with Ibrutinib. Dr. Kipps goes on to explain that the study was a cross-over study so that patients could choose to
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
_the-safety-and-efficacy-of-ibrutinib-for-the-treatment-of-cll.webp "VJHemOnc – Video Journal of Hematology u0026 HemOnc")
_cll-chemotherapy-and-ibrutinib-based-regimens.webp "HMP Education")
_what-is-hydromorphone-and-is-it-an-alternative-to-victoria39s-second-injecting-room.webp "Victoria will soon trial a new medication to try and help long-term users break their addiction. When Premier Jacinta Alan reneged on plans to set up a second safe injecting room in Melbourne this week. She committed to the trial of the pain killer Hydromorphone. Experts have welcomed it but are concerned about its small scope and the fact that it won’t begin for two years.")
_ibrutinib-resistance-mechanisms-and-options-in-cll.webp "HMP Education")
_the-safety-and-efficacy-of-ibrutinib-for-the-treatment-of-cll.jpg)
_cll-chemotherapy-and-ibrutinib-based-regimens.jpg)
_what-is-hydromorphone-and-is-it-an-alternative-to-victoria39s-second-injecting-room.jpg)
_ibrutinib-resistance-mechanisms-and-options-in-cll.jpg)
![[+]](/images/menu.gif){kind=small}